- Home
- CTNM vs RGNX Comparison
CTNM vs RGNX Comparison
Compare CTNM & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- RGNX
- Stock Information
- Founded
- CTNM 2009
- RGNX 2008
- Country
- CTNM United States
- RGNX United States
- Employees
- CTNM N/A
- RGNX N/A
- Industry
- CTNM
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTNM
- RGNX Health Care
- Exchange
- CTNM Nasdaq
- RGNX Nasdaq
- Market Cap
- CTNM 453.0M
- RGNX 459.1M
- IPO Year
- CTNM 2024
- RGNX 2015
- Fundamental
- Price
- CTNM $17.21
- RGNX $9.63
- Analyst Decision
- CTNM Strong Buy
- RGNX Strong Buy
- Analyst Count
- CTNM 4
- RGNX 12
- Target Price
- CTNM $29.25
- RGNX $36.36
- AVG Volume (30 Days)
- CTNM 74.8K
- RGNX 673.9K
- Earning Date
- CTNM 11-06-2024
- RGNX 11-06-2024
- Dividend Yield
- CTNM N/A
- RGNX N/A
- EPS Growth
- CTNM N/A
- RGNX N/A
- EPS
- CTNM N/A
- RGNX N/A
- Revenue
- CTNM N/A
- RGNX $84,327,000.00
- Revenue This Year
- CTNM N/A
- RGNX $7.91
- Revenue Next Year
- CTNM N/A
- RGNX $214.75
- P/E Ratio
- CTNM N/A
- RGNX N/A
- Revenue Growth
- CTNM N/A
- RGNX N/A
- 52 Week Low
- CTNM $13.27
- RGNX $8.54
- 52 Week High
- CTNM $22.00
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- RGNX 45.77
- Support Level
- CTNM N/A
- RGNX $10.24
- Resistance Level
- CTNM N/A
- RGNX $12.11
- Average True Range (ATR)
- CTNM 0.00
- RGNX 0.81
- MACD
- CTNM 0.00
- RGNX 0.15
- Stochastic Oscillator
- CTNM 0.00
- RGNX 29.72
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.